Michael E. Klaczko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael E. Klaczko has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- James L. McGrath
Department of Biomedical Engineering, University of Rochester, Rochester, NY 14627, USA
5 shared publications Jonathan Flax
Department of Urology, University of Rochester Medical Center, Rochester, NY, USA
3 shared publicationsAlec T. Salminen
Department of Biomedical Engineering, University of Rochester, Rochester, NY, USA
2 shared publications- Michel Godin
Department of Physics, University of Ottawa, Ottawa, ON K1N6N5, Canada
2 shared publications - Molly C. McCloskey
Department of Biomedical Engineering University of Rochester Rochester NY 14627 USA
2 shared publications A.L. Gill
Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
1 shared publication
Latest Publications
- 27 May 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale Horizons
- Vol. 11 (7) , 1965-1977
Catch-and-display immunoassay for digital biomarker detection
Digital immunoassays provide exceptional analytical sensitivity for detecting low-abundance biomarkers, but their broad adoption is limited by practical barriers. Commercial platforms are prohibitively expensive for routine use in individual laboratories, and laboratory-scale concepts typically describe specialized biosensors and sophisticated workflows. Here, we introduce a nanomembrane-based Catch-and-Display Immunoassay (CAD-IA), a cost-effective and laboratory-friendly digital immunoassay for common research settings. In CAD-IA, fluorescent nanoparticles are “captured” by the nanoscale pores of ultrathin silicon nitride membranes through a pipette powered filtration. The captured nanoparticles serve as optically isolated ‘hotspots’ for fluorescent immunocomplex formation when target antigen is present. Co-localization of the fluorescent particles and fluorescent immunocomplexes are then “displayed” and quantified by standard confocal microscopy to generate digital signals. CAD-IA is implemented using the µSiM-DX (microfluidic device featuring an ultrathin silicon membrane for diagnostics) platform, which is manually assembled from mass produced, cost-effective components. Using the traumatic brain injury (TBI) biomarker S100B as a model, we demonstrate that CAD-IA provides consistent digital outputs and linear quantification over a dynamic range of at least two orders of magnitude when digital and analog analyses are combined on the same image sets. We further demonstrate that the assay maintains linearity in serum matrices and achieves suitable sensitivity (LoD = 0.02 µg mL−1) for clinically relevant diagnostic with the addition of tyramide signal amplification (TSA). While further optimization of CAD-IA is possible, these results constitute a proof-of-concept demonstration of a novel digital immunoassay deployable in most research laboratories.
- 27 May 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale Horizons
- Vol. 11 (7) , 1965-1977
Catch-and-display immunoassay for digital biomarker detection
Digital immunoassays provide exceptional analytical sensitivity for detecting low-abundance biomarkers, but their broad adoption is limited by practical barriers. Commercial platforms are prohibitively expensive for routine use in individual laboratories, and laboratory-scale concepts typically describe specialized biosensors and sophisticated workflows. Here, we introduce a nanomembrane-based Catch-and-Display Immunoassay (CAD-IA), a cost-effective and laboratory-friendly digital immunoassay for common research settings. In CAD-IA, fluorescent nanoparticles are “captured” by the nanoscale pores of ultrathin silicon nitride membranes through a pipette powered filtration. The captured nanoparticles serve as optically isolated ‘hotspots’ for fluorescent immunocomplex formation when target antigen is present. Co-localization of the fluorescent particles and fluorescent immunocomplexes are then “displayed” and quantified by standard confocal microscopy to generate digital signals. CAD-IA is implemented using the µSiM-DX (microfluidic device featuring an ultrathin silicon membrane for diagnostics) platform, which is manually assembled from mass produced, cost-effective components. Using the traumatic brain injury (TBI) biomarker S100B as a model, we demonstrate that CAD-IA provides consistent digital outputs and linear quantification over a dynamic range of at least two orders of magnitude when digital and analog analyses are combined on the same image sets. We further demonstrate that the assay maintains linearity in serum matrices and achieves suitable sensitivity (LoD = 0.02 µg mL−1) for clinically relevant diagnostic with the addition of tyramide signal amplification (TSA). While further optimization of CAD-IA is possible, these results constitute a proof-of-concept demonstration of a novel digital immunoassay deployable in most research laboratories.
- Open Access
Catch-and-Display Immunoassay for Digital Biomarker Detection
Digital immunoassays provide exceptional analytical sensitivity for detecting low-abundance biomarkers, but their broad adoption is limited by practical barriers. Commercial platforms are prohibitively expensive for routine use by individual laboratories, and laboratory-scale concepts typically describe specialized biosensors and sophisticated workflows. Here, we introduce a nanomembrane-based Catch-and-Display Immunoassay (CAD-IA) as a cost-effective and laboratory-friendly digital immunoassay for common research settings. In CAD-IA, fluorescent nanoparticles are “captured” by the nanoscale pores of ultrathin silicon nitride membranes through a pipette powered filtration. The captured nanoparticles serve as optically isolated ‘hotspots’ for fluorescent immunocomplex formation when target antigen is present. Co-localization of the fluorescent particles and fluorescent immunocomplexes are then “displayed” and quantified by standard confocal microscopy to generate digital signals. CAD-IA is implemented using the µSiM-DX ( micro fluidic device featuring an ultrathin si licon m embrane for diagnostics ) platform, which is manually assembled from mass produced, cost-effective components. Using the traumatic brain injury (TBI) biomarker S100B as a model, we demonstrate that CAD-IA provides consistent digital outputs and linear quantification with a dynamic range of at least two orders of magnitude when digital and analog analysis are combined on the same image sets. We further demonstrate that the assay maintains linearity in serum matrices and achieves suitable sensitivity (LoD = 0.02 μg/mL) for clinically relevant diagnostic with the addition of tyramide signal amplification (TSA). While further optimization of CAD-IA is possible, these results constitute a proof-of-concept demonstration of a novel digital immunoassay deployable in most research laboratories.
Open AccessCatch-and-Display Immunoassay for Digital Biomarker Detection
Digital immunoassays provide exceptional analytical sensitivity for detecting low-abundance biomarkers, but their broad adoption is limited by practical barriers. Commercial platforms are prohibitively expensive for routine use by individual laboratories, and laboratory-scale concepts typically describe specialized biosensors and sophisticated workflows. Here, we introduce a nanomembrane-based Catch-and-Display Immunoassay (CAD-IA) as a cost-effective and laboratory-friendly digital immunoassay for common research settings. In CAD-IA, fluorescent nanoparticles are “captured” by the nanoscale pores of ultrathin silicon nitride membranes through a pipette powered filtration. The captured nanoparticles serve as optically isolated ‘hotspots’ for fluorescent immunocomplex formation when target antigen is present. Co-localization of the fluorescent particles and fluorescent immunocomplexes are then “displayed” and quantified by standard confocal microscopy to generate digital signals. CAD-IA is implemented using the µSiM-DX ( micro fluidic device featuring an ultrathin si licon m embrane for diagnostics ) platform, which is manually assembled from mass produced, cost-effective components. Using the traumatic brain injury (TBI) biomarker S100B as a model, we demonstrate that CAD-IA provides consistent digital outputs and linear quantification with a dynamic range of at least two orders of magnitude when digital and analog analysis are combined on the same image sets. We further demonstrate that the assay maintains linearity in serum matrices and achieves suitable sensitivity (LoD = 0.02 μg/mL) for clinically relevant diagnostic with the addition of tyramide signal amplification (TSA). While further optimization of CAD-IA is possible, these results constitute a proof-of-concept demonstration of a novel digital immunoassay deployable in most research laboratories.
- 11 July 2023
- Published by SAGE Publications in Journal of Dental Research
- Vol. 102 (10) , 1122-1130
The Oral Microbiome and Cross-Kingdom Interactions during Pregnancy
Pregnancy initiates a temporary transition in the maternal physiological state, with a shift in the oral microbiome and a potential increase in frequency of oral diseases. The risk of oral disease is higher among populations of Hispanic and Black women and those with lower socioeconomic status (low SES), demonstrating a need for intervention within these high-risk populations. To further our understanding of the oral microbiome of high-risk pregnant women, we characterized the oral microbiome in 28 nonpregnant and 179 pregnant low-SES women during their third trimester living in Rochester, New York. Unstimulated saliva and supragingival plaque samples were collected cross-sectionally, followed by assessment of the bacterial (16S ribosomal RNA) and fungal (18S ITS) microbiota communities. Trained and calibrated dentists performed oral examinations to determine the number of decayed teeth and plaque index. Initially, plaque from 28 nonpregnant women and 48 pregnant women were compared; these data showed significant differences in bacterial abundances based on pregnancy status. To further our understanding of the oral microbiome within the pregnant population, we next examined the oral microbiome within this population based on several variables. Streptococcus mutans, Streptococcus oralis, and Lactobacillus were associated with a greater number of decayed teeth. The composition of fungal communities differed between plaque and saliva, demonstrating 2 distinct “mycotypes” that were represented by a greater abundance of Candida in plaque and Malassezia in saliva. Veillonella rogosae, a common oral bacterium, was negatively associated with both plaque index and salivary Candida albicans colonization by culture data. This was further emphasized by in vitro inhibition of C. albicans by V. rogosae. Identification of interactions between the bacterial or fungal oral communities revealed that V. rogosae was positively associated with the oral commensal Streptococcus australis and negatively with the cariogenic Lactobacillus genus, suggesting V. rogosae as a potential biomarker of a noncariogenic oral microbiome.
- 11 July 2023
- Published by SAGE Publications in Journal of Dental Research
- Vol. 102 (10) , 1122-1130
The Oral Microbiome and Cross-Kingdom Interactions during Pregnancy
Pregnancy initiates a temporary transition in the maternal physiological state, with a shift in the oral microbiome and a potential increase in frequency of oral diseases. The risk of oral disease is higher among populations of Hispanic and Black women and those with lower socioeconomic status (low SES), demonstrating a need for intervention within these high-risk populations. To further our understanding of the oral microbiome of high-risk pregnant women, we characterized the oral microbiome in 28 nonpregnant and 179 pregnant low-SES women during their third trimester living in Rochester, New York. Unstimulated saliva and supragingival plaque samples were collected cross-sectionally, followed by assessment of the bacterial (16S ribosomal RNA) and fungal (18S ITS) microbiota communities. Trained and calibrated dentists performed oral examinations to determine the number of decayed teeth and plaque index. Initially, plaque from 28 nonpregnant women and 48 pregnant women were compared; these data showed significant differences in bacterial abundances based on pregnancy status. To further our understanding of the oral microbiome within the pregnant population, we next examined the oral microbiome within this population based on several variables. Streptococcus mutans, Streptococcus oralis, and Lactobacillus were associated with a greater number of decayed teeth. The composition of fungal communities differed between plaque and saliva, demonstrating 2 distinct “mycotypes” that were represented by a greater abundance of Candida in plaque and Malassezia in saliva. Veillonella rogosae, a common oral bacterium, was negatively associated with both plaque index and salivary Candida albicans colonization by culture data. This was further emphasized by in vitro inhibition of C. albicans by V. rogosae. Identification of interactions between the bacterial or fungal oral communities revealed that V. rogosae was positively associated with the oral commensal Streptococcus australis and negatively with the cariogenic Lactobacillus genus, suggesting V. rogosae as a potential biomarker of a noncariogenic oral microbiome.
- Open Access
- 4 October 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (10) , 1351
Identification of Staphylococcus aureus Penicillin Binding Protein 4 (PBP4) Inhibitors
Methicillin-resistant Staphylococcus aureus (MRSA) is a global healthcare concern. Such resistance has historically been attributed to the acquisition of mecA (or mecC), which encodes an alternative penicillin binding protein, PBP2a, with low β-lactam affinity. However, recent studies have indicated that penicillin binding protein 4 (PBP4) is also a critical determinant of S. aureus methicillin resistance, particularly among community-acquired MRSA strains. Thus, PBP4 has been considered an intriguing therapeutic target as corresponding inhibitors may restore MRSA β-lactam susceptibility. In addition to its role in antibiotic resistance, PBP4 has also recently been shown to be required for S. aureus cortical bone osteocyte lacuno-canalicular network (OLCN) invasion and colonization, providing the organism with a niche for re-occurring bone infection. From these perspectives, the development of PBP4 inhibitors may have tremendous impact as agents that both reverse methicillin resistance and inhibit the organism’s ability to cause chronic osteomyelitis. Accordingly, using a whole-cell high-throughput screen of a 30,000-member small molecule chemical library and secondary assays we identified putative S. aureus PBP4 inhibitors. Quantitative reverse transcriptase mediated PCR and PBP4 binding assays revealed that hits could be further distinguished as compounds that reduce PBP4 expression versus compounds that are likely to affect the protein’s function. We also showed that 6.25 µM (2.5 µg/mL) of the lead candidate, 9314848, reverses the organism’s PBP4-dependent MRSA phenotype and inhibits its ability to traverse Microfluidic-Silicon Membrane-Canalicular Arrays (µSiM-CA) that model the OLCN orifice. Collectively, these molecules may represent promising potential as PBP4-inhibitors that can be further developed as adjuvants for the treatment of MRSA infections and/or osteomyelitis prophylactics.
- 4 October 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (10) , 1351
Open AccessIdentification of Staphylococcus aureus Penicillin Binding Protein 4 (PBP4) Inhibitors
Methicillin-resistant Staphylococcus aureus (MRSA) is a global healthcare concern. Such resistance has historically been attributed to the acquisition of mecA (or mecC), which encodes an alternative penicillin binding protein, PBP2a, with low β-lactam affinity. However, recent studies have indicated that penicillin binding protein 4 (PBP4) is also a critical determinant of S. aureus methicillin resistance, particularly among community-acquired MRSA strains. Thus, PBP4 has been considered an intriguing therapeutic target as corresponding inhibitors may restore MRSA β-lactam susceptibility. In addition to its role in antibiotic resistance, PBP4 has also recently been shown to be required for S. aureus cortical bone osteocyte lacuno-canalicular network (OLCN) invasion and colonization, providing the organism with a niche for re-occurring bone infection. From these perspectives, the development of PBP4 inhibitors may have tremendous impact as agents that both reverse methicillin resistance and inhibit the organism’s ability to cause chronic osteomyelitis. Accordingly, using a whole-cell high-throughput screen of a 30,000-member small molecule chemical library and secondary assays we identified putative S. aureus PBP4 inhibitors. Quantitative reverse transcriptase mediated PCR and PBP4 binding assays revealed that hits could be further distinguished as compounds that reduce PBP4 expression versus compounds that are likely to affect the protein’s function. We also showed that 6.25 µM (2.5 µg/mL) of the lead candidate, 9314848, reverses the organism’s PBP4-dependent MRSA phenotype and inhibits its ability to traverse Microfluidic-Silicon Membrane-Canalicular Arrays (µSiM-CA) that model the OLCN orifice. Collectively, these molecules may represent promising potential as PBP4-inhibitors that can be further developed as adjuvants for the treatment of MRSA infections and/or osteomyelitis prophylactics.
- Open Access
- 11 May 2022
- Published by Elsevier in European Journal of Cell Biology
- Vol. 101 (3) , 151233
Molecular mechanisms underlying the heterogeneous barrier responses of two primary endothelial cell types to sphingosine-1-phosphate
- 11 May 2022
- Published by Elsevier in European Journal of Cell Biology
- Vol. 101 (3) , 151233
Open AccessMolecular mechanisms underlying the heterogeneous barrier responses of two primary endothelial cell types to sphingosine-1-phosphate
- Open Access
- 31 December 2021
- Published by American Chemical Society (ACS) in ChemRxiv
Alloying and Phase Transformation of Fe/FeNi Core/Alloy Nanoparticles at High Temperatures
This work explores how to form and tailor the alloy composition of Fe/FexNi1-x core/alloy nanoparticles by annealing a pre-formed particle at elevated temperatures between 180 – 325 oC. This annealing allowed for a systematic FeNi alloying at a nanoparticle whose compositions and structure began as a alpha-Fe rich core, and a thin gamma-Ni rich shell, into mixed phases resembling gamma-FeNi3 and gamma-Fe3Ni2. This was possible in part by controlling surface diffusion via annealing temperature, and the enhanced diffusion at the many grain boundaries of the nanoparticle. Lattice expansion and phase change was characterized by powder X-ray diffraction (XRD), and composition was monitored by X-ray photoelectron spectroscopy (XPS). Of interest is that no phase precipitation was observed (i.e., heterostructure formation) in this system and the XRD results suggest that alloying composition or alloy gradient is uniform. This uniform alloying was considered using calculations of bulk diffusion and grain boundary diffusion for Fe and Ni self-diffusion, as well as Fe-Ni impurity diffusion is provided. In addition, alloying was further considered by calculations for Fe-Ni mixing enthalpy (Hmix) and phase segregation enthalpy (HSeg) using the Miedema model, which allowed for the consideration of alloying favorability or core-shell segregation in the alloying, respectively. Of particular interest is the formation of stable metal carbides compositions, which suggest that the typically inert organic self-assembled monolayer encapsulation can also be internalized.
- 31 December 2021
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAlloying and Phase Transformation of Fe/FeNi Core/Alloy Nanoparticles at High Temperatures
This work explores how to form and tailor the alloy composition of Fe/FexNi1-x core/alloy nanoparticles by annealing a pre-formed particle at elevated temperatures between 180 – 325 oC. This annealing allowed for a systematic FeNi alloying at a nanoparticle whose compositions and structure began as a alpha-Fe rich core, and a thin gamma-Ni rich shell, into mixed phases resembling gamma-FeNi3 and gamma-Fe3Ni2. This was possible in part by controlling surface diffusion via annealing temperature, and the enhanced diffusion at the many grain boundaries of the nanoparticle. Lattice expansion and phase change was characterized by powder X-ray diffraction (XRD), and composition was monitored by X-ray photoelectron spectroscopy (XPS). Of interest is that no phase precipitation was observed (i.e., heterostructure formation) in this system and the XRD results suggest that alloying composition or alloy gradient is uniform. This uniform alloying was considered using calculations of bulk diffusion and grain boundary diffusion for Fe and Ni self-diffusion, as well as Fe-Ni impurity diffusion is provided. In addition, alloying was further considered by calculations for Fe-Ni mixing enthalpy (Hmix) and phase segregation enthalpy (HSeg) using the Miedema model, which allowed for the consideration of alloying favorability or core-shell segregation in the alloying, respectively. Of particular interest is the formation of stable metal carbides compositions, which suggest that the typically inert organic self-assembled monolayer encapsulation can also be internalized.
- 10 December 2021
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 147 (2) , 213-222
Rapid and specific detection of intact viral particles using functionalized microslit silicon membranes as a fouling-based sensor
The COVID-19 pandemic demonstrated the public health benefits of reliable and accessible point-of-care (POC) diagnostic tests for viral infections. Despite the rapid development of gold-standard reverse transcription polymerase chain reaction (RT-PCR) assays for SARS-CoV-2 only weeks into the pandemic, global demand created logistical challenges that delayed access to testing for months and helped fuel the spread of COVID-19. Additionally, the extreme sensitivity of RT-PCR had a costly downside as the tests could not differentiate between patients with active infection and those who were no longer infectious but still shedding viral genomes. To address these issues for the future, we propose a novel membrane-based sensor that only detects intact virions. The sensor combines affinity and size based detection on a membrane-based sensor and does not require external power to operate or read. Specifically, the presence of intact virions, but not viral debris, fouls the membrane and triggers a macroscopically visible hydraulic switch after injection of a 40 μL sample with a pipette. The device, which we call the μSiM-DX (microfluidic device featuring a silicon membrane for diagnostics), features a biotin-coated microslit membrane with pores ∼2–3× larger than the intact virus. Streptavidin-conjugated antibody recognizing viral surface proteins are incubated with the sample for ∼1 hour prior to injection into the device, and positive/negative results are obtained within ten seconds of sample injection. Proof-of-principle tests have been performed using preparations of vaccinia virus. After optimizing slit pore sizes and porous membrane area, the fouling-based sensor exhibits 100% specificity and 97% sensitivity for vaccinia virus (n = 62). Moreover, the dynamic range of the sensor extends at least from 105.9 virions per mL to 1010.4 virions per mL covering the range of mean viral loads in symptomatic COVID-19 patients (105.6–107 RNA copies per mL). Forthcoming work will test the ability of our sensor to perform similarly in biological fluids and with SARS-CoV-2, to fully test the potential of a membrane fouling-based sensor to serve as a PCR-free alternative for POC containment efforts in the spread of infectious disease.
- 10 December 2021
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 147 (2) , 213-222
Rapid and specific detection of intact viral particles using functionalized microslit silicon membranes as a fouling-based sensor
The COVID-19 pandemic demonstrated the public health benefits of reliable and accessible point-of-care (POC) diagnostic tests for viral infections. Despite the rapid development of gold-standard reverse transcription polymerase chain reaction (RT-PCR) assays for SARS-CoV-2 only weeks into the pandemic, global demand created logistical challenges that delayed access to testing for months and helped fuel the spread of COVID-19. Additionally, the extreme sensitivity of RT-PCR had a costly downside as the tests could not differentiate between patients with active infection and those who were no longer infectious but still shedding viral genomes. To address these issues for the future, we propose a novel membrane-based sensor that only detects intact virions. The sensor combines affinity and size based detection on a membrane-based sensor and does not require external power to operate or read. Specifically, the presence of intact virions, but not viral debris, fouls the membrane and triggers a macroscopically visible hydraulic switch after injection of a 40 μL sample with a pipette. The device, which we call the μSiM-DX (microfluidic device featuring a silicon membrane for diagnostics), features a biotin-coated microslit membrane with pores ∼2–3× larger than the intact virus. Streptavidin-conjugated antibody recognizing viral surface proteins are incubated with the sample for ∼1 hour prior to injection into the device, and positive/negative results are obtained within ten seconds of sample injection. Proof-of-principle tests have been performed using preparations of vaccinia virus. After optimizing slit pore sizes and porous membrane area, the fouling-based sensor exhibits 100% specificity and 97% sensitivity for vaccinia virus (n = 62). Moreover, the dynamic range of the sensor extends at least from 105.9 virions per mL to 1010.4 virions per mL covering the range of mean viral loads in symptomatic COVID-19 patients (105.6–107 RNA copies per mL). Forthcoming work will test the ability of our sensor to perform similarly in biological fluids and with SARS-CoV-2, to fully test the potential of a membrane fouling-based sensor to serve as a PCR-free alternative for POC containment efforts in the spread of infectious disease.